Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Rodríguez‐Morales, Alfonso J.; Bonilla-Aldana, D. Katterine; Suárez, José Antonio; Franco‐Paredes, Carlos; Forero‐Peña, David A.; Máttar, Salim; Villamil-Gómez, Wilmer E.; Ruíz-Saenz, Julián; Cardona-Ospina, Jaime A.; Figuera, Manuel; Sierra, Leandro; Rísquez, Alejandro; Cimerman, Sérgio; Valero-Cedeño, Nereida Josefina; Cabrera, Maritza; Robaina-Barrios, Andrea J; López-Dı́az, L.; Barbella, Rosa; Navas, Rosa M.; Díaz-Quijano, Fredi Alexander; Carrero, Yenddy; Pineda, Anishmenia; Brito, Maximo O.; Savio-Larriera, Eduardo; Martínez-Gutiérrez, Marlen; Maquera-Afaray, Julio; Solarte-Portilla, Marco A.; Hernández-Botero, Sebastián; Contreras, Krisell; Lopez, M.; Henao-Martínez, Andrés F; Ortiz-Martínez, Yeimer; Chaves, Tânia; Orduña, Tomás; Lepetic, Alejandro; Macchi, Alejandra; Verbanaz, Sergio; Perret, Cecilia; Echazarreta, Sofía; Lloveras, Susana; Gallego, Viviana; Navarro, Juan Carlos; Paniz‐Mondolfi, Alberto

doi:10.1016/j.tmaid.2021.102192

Cited by 13 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many YF endemic countries have experienced recent outbreaks or resurgence of cases. 3 PLWH wishing to travel to these areas will, therefore, have to be vaccinated against YF, either on administrative or epidemiological grounds.…”

Section: Introductionmentioning

confidence: 99%

Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity

Martin

Florence

Domingo

et al. 2022

Journal of Travel Medicine

View full text Add to dashboard Cite

Background: Data on seroconversion rates following yellow fever (YF) vaccine and effect of revaccination in people living with HIV (PLWH) are scarce. We aimed at determining key factors for seroconversion after YF vaccine in PLWH and the role of preexisting neutralizing antibodies (NAbs) at vaccination. Methods: A retrospective cross-sectional study at several timepoints in two Belgian AIDS Reference Center. For each individual, plasma samples from three timepoints were selected: Timepoint 0 (TP0) in the year before administration of the YF vaccine, Timepoint 1 (TP1) in the year following the YF vaccine, Timepoint 2 (TP2) more than one year after the YF vaccine. Plasma samples were analyzed for YF NAbs by plaque reduction neutralization test. The primary endpoint was the number of patients with protective levels of NAbs≥1/10. A boosted immune response was defined as a 4-fold increase in serologic titers following revaccination. Results: Of the 160 PLWH included, protective levels of NAbs were present in 36%, 87% and 72% of subjects at baseline, at a median of 12 months and a median of 96 months after YF vaccination, respectively. Among vaccinees negative for YF NAbs at baseline (n = 102), 83% seroconverted. PLWH with undetectable HIV viral load (VL) at baseline were more likely to seroconvert (p < 0·01). A booster response was observed in only 17% of subjects with baseline seropositivity (n = 10 out of 58). In multivariate analysis, undetectable HIV VL at vaccination and baseline YF seropositivity were associated with persistent levels of protective NAbs at a median of 8 years after YF vaccination. Conclusion: Undetectable HIV VL at baseline is associated with high rates of seroconversion. YF seropositivity before revaccination is associated with low rates of booster effect but a higher chance of long term persistent NAbs response, suggesting a benefit of revaccination in PLWH.

show abstract

Section: Introductionmentioning

confidence: 99%

Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity

Martin

Florence

Domingo

et al. 2022

Journal of Travel Medicine

View full text Add to dashboard Cite

show abstract

“…These events marked dengue as an emerging disease in the America [11,12]. As observed, flaviviruses, such as dengue and yellow fever, have been significant concerns regarding morbidity and mortality in the region [4,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. Additionally, many of them, as observed with Zika (ZIKV) and chikungunya (CHIKV), lead to chronic consequences, such as central nervous system (CNS) compromise (including congenital microcephaly and other complications of congenital Zika syndrome) [28][29][30][31][32], as well as chronic rheumatic and non-rheumatic diseases (CHIKV) [33][34][35][36][37][38][39].…”

Section: Introductionmentioning

confidence: 99%

Neglected Arboviruses in Latin America

Rodríguez‐Morales¹,

Bonilla-Aldana²

2023

New Advances in Neglected Tropical Diseases

View full text Add to dashboard Cite

Over the last decade, there has been an increasing concern for epidemics in Latin America, as well as in other regions, due to arboviruses causing epidemics. Before 2013, dengue and yellow fever were of major preoccupation in urban and rural areas, respectively. But after that year, the emergence of chikungunya (2013) and Zika (2015) with their widespread in the region, affected millions of individuals, especially in tropical countries. Nowadays, other alpha and flaviviruses, but also bunyaviruses, have been circulating in the region causing small outbreaks, as is the case of Mayaro, Madariaga, Rocio, Oropouche, and St. Louis encephalitis, among others. In the current chapter, we address the situation regarding these other arboviruses that have been neglected by also being a differential diagnosis and an etiology of febrile syndrome in the region.

show abstract

“…La selva central de Perú es la segunda región que reporta mayor número de casos de esta arbovirosis con incremento de afectados en los últimos años, en el año 2019 informaron 61 casos confirmados de fiebre amarilla y 252 casos confirmados de dengue grave siendo este número el doble en relación al año 2018 (Guzmán et al, 2018;OMS, 2020;Rodríguez et al, 2021). Los casos graves de estas patologías fueron remitidos al Hospital Daniel Alcides Carrión ubicado en la región central del Perú.…”

Section: Introductionunclassified

Comparación clínica y laboratorial de la fiebre amarilla severa versus dengue grave en Perú

Montalvo

Díaz-Lazo²,

Montalvo³

et al. 2022

BMSA

View full text Add to dashboard Cite

En los centros de Emergencia con poco apoyo de laboratorio, es difícil diferenciar a los pacientes con dengue grave y fiebre amarilla severa. El objetivo fue comparar el perfil clínico y de laboratorio de los pacientes con dengue grave y fiebre amarilla severa en Urgencias. Se realizó un estudio observacional retrospectivo de pacientes con diagnóstico confirmado de dengue y fiebre amarilla en el período 2018 a 2020 atendidos en la Unidad de Emergencia del Hospital Carrión, Huancayo-Perú. Se evaluaron un total de 35 pacientes, 11 pacientes (31,4%) fueron diagnosticados con fiebre amarilla severa y 24 pacientes (68,5%) con dengue grave. La media de los resultados de laboratorio con fiebre amarilla severa fueron bilirrubina indirecta 4,7 ml/dL, aspartato transaminasa 4463 UI/L, transaminasa aminotransferasa 4329 UI/L, creatinina 4,9 mg/dl. En pacientes con dengue grave el hematocrito promedio fue 51,8, hemoglobina 17,6 g/dl, plaquetas 24 × 103/mm. En pacientes con síndrome ictérico-febril la presencia de bradicardia, bilirrubina indirecta elevada y transaminasas muy elevadas debe hacer sospechar de fiebre amarilla; mientras que los pacientes que acuden por ascitis, derrame pleural, aumento de hematocrito y deficiencia de plaquetas, se debe tratar como dengue grave sobre todo en Unidades de Emergencia con poco apoyo de laboratorio.

show abstract

Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Cited by 13 publications

References 44 publications

Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity

Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity

Neglected Arboviruses in Latin America

Comparación clínica y laboratorial de la fiebre amarilla severa versus dengue grave en Perú

Contact Info

Product

Resources

About